Rosanne Graham - Evotec SE CEO
| EVO Stock | USD 5.37 0.12 2.29% |
CEO
Rosanne Graham is CEO of Evotec SE ADR
| Address | Essener Bogen 7, Hamburg, Germany, 22419 |
| Phone | 49 40 560 81 0 |
| Web | https://www.evotec.com |
Evotec SE Management Efficiency
As of the 3rd of May 2024, Return On Tangible Assets is likely to drop to -0.04. In addition to that, Return On Capital Employed is likely to drop to -0.06. At this time, Evotec SE's Intangibles To Total Assets are very stable compared to the past year. As of the 3rd of May 2024, Debt To Assets is likely to grow to 0.29, while Other Assets are likely to drop 1.09. Evotec SE's management efficiency ratios could be used to measure how well Evotec SE manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | CEO Age | ||
| Jan DAlvise | Acasti Pharma | N/A | |
| Cary MBA | Adial Pharmaceuticals | 63 | |
| Teofilo Raad | Pulmatrix | 48 | |
| Janelle DAlvise | Acasti Pharma | 69 | |
| Robert Clarke | Pulmatrix | 46 | |
| Teofilo MBA | Pulmatrix | 54 | |
| William Stilley | Adial Pharmaceuticals | 49 | |
| Lisa Conte | Jaguar Animal Health | 65 | |
| Ted Raad | Pulmatrix | 48 | |
Management Performance
| Return On Equity | -0.0727 | ||||
| Return On Asset | 3.0E-4 |
Evotec SE ADR Leadership Team
Elected by the shareholders, the Evotec SE's board of directors comprises two types of representatives: Evotec SE inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evotec. The board's role is to monitor Evotec SE's management team and ensure that shareholders' interests are well served. Evotec SE's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evotec SE's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anthony Quirk, Non-Independent Non-Executive Director | ||
| Matthias Evers, Chief Board | ||
| Mark Finlay, CEO | ||
| Jenny Yule, CEO - Porse | ||
| Monika Conradt, Global Resources | ||
| Valerie Mosley, Independent Trustee | ||
| Christian Dargel, EVP Compliance | ||
| Payson Swaffield, Vice President | ||
| Daniel Cataldo, Treasurer - IR Contact Officer | ||
| Vivek Singh, CFO, Company Secretary | ||
| Anja Bosler, Principal Accounting | ||
| Thomas Faust, Trustee | ||
| Harriett Taggart, Independent Trustee | ||
| Norah Barlow, Independent Director | ||
| Volker Braun, Executive ESG | ||
| Paul ONeil, Chief Compliance Officer | ||
| Scott Eston, Independent Trustee | ||
| Ralph Verni, Independent Chairman of the Board of Trustees | ||
| Rachel Nottingham, Acquisitions and Property Manager | ||
| Cord Dohrmann, Chief Board | ||
| George Gorman, Independent Trustee | ||
| Grainne Troute, Independent Non-Executive Director | ||
| Craig Johnstone, COO Board | ||
| William Park, Independent Trustee | ||
| James Kirchner, Treasurer | ||
| Rosanne Graham, CEO | ||
| Hamish Stevens, Independent Director | ||
| Mario DPHIL, Member CEO | ||
| Maureen Gemma, Chief Legal Officer, VP and Secretary | ||
| MBA MPA, Member Board | ||
| Helen Peters, Independent Trustee | ||
| Cynthia Frost, Independent Trustee | ||
| Beverley Gordon, Financial Controller | ||
| Lynda Reid, Independent Non-Executive Director | ||
| Ronald Pearlman, Independent Trustee | ||
| Enno Spillner, CFO Board | ||
| Kirsten Long, General Manager - Centre Operations | ||
| MBA MBA, Chairman CEO | ||
| Gabriele Hansen, Senior Marketing | ||
| Paula Hawkings, General Manager - Lollipops Educare | ||
| Laetitia Rouxel, CFO Board | ||
| Alistair Ryan, Non-Executive Chairman of the Board |
Evotec Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evotec SE a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0727 | ||||
| Return On Asset | 3.0E-4 | ||||
| Profit Margin | (0.11) % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 951 M | ||||
| Shares Outstanding | 354.37 M | ||||
| Shares Owned By Institutions | 1.56 % | ||||
| Number Of Shares Shorted | 59.21 K | ||||
| Price To Earning | 444.00 X | ||||
| Price To Book | 2.12 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Evotec SE in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Evotec SE's short interest history, or implied volatility extrapolated from Evotec SE options trading.
Pair Trading with Evotec SE
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Evotec SE position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Evotec SE will appreciate offsetting losses from the drop in the long position's value.Moving against Evotec Stock
| 0.74 | JAGX | Jaguar Animal Health Financial Report 20th of May 2024 | PairCorr |
| 0.69 | ELYM | Eliem Therapeutics Trending | PairCorr |
| 0.42 | OGN | Organon | PairCorr |
The ability to find closely correlated positions to Evotec SE could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Evotec SE when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Evotec SE - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Evotec SE ADR to buy it.
The correlation of Evotec SE is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Evotec SE moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Evotec SE ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Evotec SE can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evotec SE ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Complementary Tools for Evotec Stock analysis
When running Evotec SE's price analysis, check to measure Evotec SE's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evotec SE is operating at the current time. Most of Evotec SE's value examination focuses on studying past and present price action to predict the probability of Evotec SE's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evotec SE's price. Additionally, you may evaluate how the addition of Evotec SE to your portfolios can decrease your overall portfolio volatility.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Evotec SE's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evotec SE. If investors know Evotec will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evotec SE listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.25) | Revenue Per Share 2.2085 | Quarterly Revenue Growth (0.16) | Return On Assets 0.0003 | Return On Equity (0.07) |
The market value of Evotec SE ADR is measured differently than its book value, which is the value of Evotec that is recorded on the company's balance sheet. Investors also form their own opinion of Evotec SE's value that differs from its market value or its book value, called intrinsic value, which is Evotec SE's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evotec SE's market value can be influenced by many factors that don't directly affect Evotec SE's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evotec SE's value and its price as these two are different measures arrived at by different means. Investors typically determine if Evotec SE is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evotec SE's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.